59 results about "Antitumor Antibiotics" patented technology

This invention relates to a combined preparation for simultaneous, separate, or sequential administration in the treatment of cancer, comprising two separate preparations:

a preparation comprising, in combination with a pharmaceutically acceptable carrier or diluent, at least one compound of general formula I:

wherein

• • R¹ and R² each independently represent a hydrogen atom, lower alkyl, or the like, and G represents pentosyl or the like, X¹ and X² each independently represent a hydrogen atom, a halogen atom, or the like or a pharmaceutically acceptable salt thereof; and a preparation, in combination with a pharmaceutically acceptable carrier or diluent, such as antitumor alkylating agents, antitumor antimetabolites, antitumor antibiotics, or plant-derived antitumor agents (a preparation comprising at least one compound of general formula I or a pharmaceutically acceptable salt thereof may be combined with two or more other antitumor agents), and a method for cancer treatment comprising the administration of these preparations in combination.

The present invention provides a fermentation method of high-yield antitumor antibiotic calicheamicin. The method of the invention employs Micromonospora echinospora for fermentation production of calicheamicin in a fermentation medium added with different kinds of macroporous adsorption resins. The method of the present invention has stable process and substantially increased fermentation yield.

The invention provides a novel compound having a structural formula (I), and a pharmaceutically acceptable salts formed by the compound. The compound is obtained by fermentation culture of producing bacteria thereof. The compound is the novel compound of a bleomycin group, has better antitumor activity than that of the clinical bleomycin, and can be used for preparing an antitumor medicament.

The invention provides a method for preparing a nano micelle preparation of anthracycline antitumor antibiotics, including the following steps: (1) dissolving anthracycline antitumor antibiotics in water or medicinal buffer salt solution; (2) dissolving polyethylene glycol-phospholipid in water or medicinal buffer salt solution; (3) mixing the solution in step (1) and the solution in step (2) and hydrating the mixture at 25 DEG C to 60 DEG C to obtain the nano micelle of anthracycline antitumor antibiotics. Compared with the prior art, the method of the invention is simple and easy to operate, does not need complex large-scale instruments, and is suitable for industrial production, and the obtained nano micelle preparation does not contain nano organic solvent.

The invention discloses an antharcycline antitumor antibiotics loaded nano-micelle preparation, which comprises antharcycline antitumor antibiotics, A-B-C type triblock polymer and assisting agents, wherein the antharcycline antitumor antibiotics is one or more of adriamycin, daunorubicin, pharmorubicin, perarubicin or lacinomycin; and the A-B-C type triblock polymer is polyethylene glycol-polyethylene glycol containing carboxyl on side chain-polyester. According to the preparation, drugs are coated in the nano-micelle by virtue of the coaction of self-assembly of segmented copolymer and electrostatic adsorption, the nano-micelle has uniform and stable grain diameter, the encapsulation efficiency reaches 99 percent, and the prepared nano-micelle preparation is of a spherical structure with grain diameter between 20 and 300nm; and the shell of the micelle is made from polyethylene glycol molecules, so that drugs are prevented from being contacted with enzyme and other protein molecules in blood or identified and swallowed by a reticuloendothelial system in the body, so that the circulating period of micelle in the body can be prolonged.

The present invention relates to compositions and methods for treating cancer, by administering a combination comprising a jasmonate derivative (e.g., methyl jasmonate or a compound of any of formulae I through VII or any of the jasmonate derivatives exemplified by such formulae) and at least one other agent selected from a chemotherapeutic agent (e.g., a nitroso-urea, a platinum compound, a taxane derivative, an antitumor antibiotic) and an inhibitor of glycolysis (e.g., 2-deoxy-D-glucose). The jasmonate derivative and the at least one other agent together provide a therapeutic effect, which is preferably synergistic (cooperative).

The slow released compound anticancer injection containing bendamustine consists of slow released microsphere and solvent. The slow released microsphere includes effective anticancer component and slow releasing supplementary material, and the solvent is special solvent containing suspending agent. The effective anticancer component is the composition of bendamustine and bendamustine synergist selected from antitumor antibiotic and antimetabolite. The slow releasing supplementary material is polylactic acid and its copolymer, polifeprosan, EVAc, etc or their composition. The .suspending agent has viscosity of 80-3000 cp. The slow released microsphere may be also prepared into slow released implanting agent. The present invention can inhibit the growth of tumor and enhance the curative effect of chemotherapy, radiotherapy and other non-operative treatment.

The present invention provides a nano-micellar preparation of anthracycline antitumor antibiotics for intravenous injection, which comprises a therapeutically effective amount of anthracycline antitumor antibiotics, a phosphatide derivatized with polyethylene glycol, together with pharmaceutically acceptable adjuvants. The preparation is prepared by encapsulating the medicament with a nano-micelle to obtain the nano-micellar preparation of anthracycline antitumor antibiotics for injection. The anthracycline antitumor antibiotics and the phosphatide derivatized with polyethylene glycol form a nano-micelle with a highly homogeneous particle size. In the micelle, the hydrophobic core of encapsulated medicament is surrounded by polyethylene glycol molecules to form a hydrophilic protective layer, so that the medicament is prevented from contacting with the enzymes and other protein molecules in blood and being recognized and phagocytozed by reticuloendothelial system in the body, and the circulation time in vivo of the micelle is prolonged.

A pyranyl nequinone anti-neoplastic antibiotic is prepared by fermenting, culturing Nocardiopsis sp. YIM 80133, separating out from fermented liquid, purifying extract to obtain final product with molecular formula C21H20010 and molecular weight 432.38. It has strong inhibiting function of human progranuleukemic tumor cell.

The slow released compound anticancer injection containing bendamustine consists of slow released microsphere and solvent. The slow released microsphere includes effective anticancer component and slow releasing supplementary material, and the solvent is special solvent containing suspending agent. The effective anticancer component is the composition of bendamustine and bendamustine synergist selected from antitumor antibiotic and antimetabolite. The slow releasing supplementary material is polylactic acid/glycolic acid copolymer, polyethylene glycol/polylactic acid, EVAc, etc. The .suspending agent is carboxymethyl cellulose, etc. and has viscosity of 80-3000 cp at 20-30 deg.c. The slow released microsphere may be also prepared into slow released implanting agent. The present invention can inhibit the growth of tumor effectively and enhance the curative effect of chemotherapy, radiotherapy and other non-operative treatment.

The invention relates to derivatives of a cytidine peptide compound, and specifically relates to ancomycin methyl ester, isopropyl ester and isopentyl ester. Wherein, carboxyl in position 5' of the hexose ring in the fermentation product ancomycin of streptomyces albulus C-9095 is connected with the methyl, isopropyl and isopentyl respectively for esterification through different chemosynthesis methods, thus obtaining the relevant ancomycin ester derivatives. Experimental research both in vivo and in vitro proves that the derivatives have inhibitory effects on relevant tumor cells, thus being hopeful to be developed as antitumor medicaments.

The slow released anticancer injection consists of slow released microballoon and solvent. The slow released microballoon includes effective anticancer component and slow releasing supplementary material, and the solvent is common solvent or special solvent containing suspending agent. The effective anticancer component is 5-FU synergist or the combination of 5-FU and 5-FU synergist selected from antitumor antibiotic, antimetabolite, taxane and plant alkaloid; the slow releasing supplementary material is PLA, PLGA, EVAc, etc or their composition; and the suspending agent is sodium carboxymethyl cellulose, mannitol, sorbitol, Tween-80 or their composition. The slow released microballoon may be also prepared into slow released implantation preparation. Implanting or injecting the slow released preparation to local tumor part can lower the systematic toxic reaction of the medicine and raise the medicine concentration of local tumor part selectively to raise the treating effect.

Disclosed is a method of predicting clinical tumor outcome by providing gene expression from a tumor sample. The method utilizes a novel genetic screen to identify genes that contribute to chemotherapeutic responsiveness, using formalin fixed paraffin embedded clinical samples of epithelial cancer, specifically serous ovarian cancer. The method is useful in predicting tumor responsiveness to chemotherapeutics, including alkylating agents, cisplatin, antimetabolites, plant alkaloids, and antitumor antibiotics. A microarray screen showed formalin fixed paraffin embedded samples can identify genes related to chemotherapeutic response with 86% efficiency.

The present Invention relates to a method of treating a warm-blooded animal having acute myeloid leukemia (AML) which is resistant to conventional chemotherapy, comprising administering to said animal a therapeutically effective amount of a compound of formula (I), wherein the radicals and symbols have the meanings as defined in the specification, together or in combination with a conventional compound or compound mixture useful in AML treatment, in particular a topoisomerase II inhibitor, an antimetabolite, or an antitumor antibiotic, for simultaneous, separate or sequential use; and to a pharmaceutical composition and a commercial package comprising said combination.

The invention relates to an antitumor active substance generated by streptosporangium C-3560. The antitumor active protein molecular weight is 10.8kDa, and the N-end sequence is shown as a sequence table SEQ ID No.1. Active substance biology experimental study results prove that obvious antitumor activity is realized on various kinds of tumor cells in-vitro culture, the tumor cell apoptosis can be induced, and in addition, the cell cycle arrest is generated. In-vitro animal experiments prove that the tumor growth of mouse H22 liver cancer can be obviously inhibited, and the antitumor active substance is hopeful to further develope into clinical efficient antitumor medicine.

The present invention relates to a compound anticarcinogen slow-released injection containing vasoinhibitor and its synergist. It is composed of slow-released microsphere and solvent. The slow-released microsphere includes anticancer effective component and slow-released auxiliary material, the solvent is general solvent or special solvent containing suspension adjuvant. The anticancer effective component is combination of vasoinhibitor and vasoinhibitor synergist of antitumor antibiotic or antimetabolite medicine, the slow-released auxiliary material is one selected from racemic polylactic acid and its copolymer, monomethyl polyethylene glycol and polylactic acid copolymer, polyethylene glycol and polylactic acid copolymer, carboxyl terminated polylactic acid and glycollic acid copolymer and ethylene-vinylacetate, etc. or their combination. The viscosity of suspension adjuvant is 100 cp-3000 cp, said suspension adjuvant is selected from sodium cellulose glycollate. The slow-released microsphere also can be made into slow-released implant preparation. Said invention also provides its application method for curing various tumors and cancers.

An anti-vascular diseases and antitumor pharmaceutical composition is provided in the present invention, and it includes effective ingredients including bleomycin antitumor antibiotic, adrenal glucocorticoid, epinephrine or pharmaceutically acceptable salts thereof in a weight ratio of (1-8):(2-5):(0.00005-0.001). The pharmaceutical composition provided can be used for treatment of vascular diseases and tumors.

The present invention discloses an anthracycline antitumor antibiotic albumin conjugate comprising an anthracycline antitumor antibiotic or a pharmaceutically acceptable salt thereof and albumin in aweight ratio of 1:1 to 1000. The invention also discloses lyophilized powder for injection, a preparation, application and a preparation method of the anthracycline antitumor antibiotic albumin conjugate. The anthracycline antitumor antibiotic albumin conjugate has high efficiency, low toxicity, good drug stability, simple preparation method and convenient clinical use.

The slow released compound anticancer injection containing blood vessel inhibitor and its synergist consists of slow released microsphere and solvent. The slow released microsphere includes effective anticancer component and slow releasing supplementary material, and the solvent is common solvent or special solvent containing suspending agent. The effective anticancer component is blood vessel inhibitor and/or blood vessel inhibitor synergist selected from antitumor antibiotic and antimetabolite. The slow releasing supplementary material is selected from difatty acid-sebacic acid copolymer, poly(erucic acid dipolymer-sebacic acid), poly(fumaric acid-sebacic acid), etc or their composition. The suspending agent is carboxymethyl cellulose, etc. and has viscosity of 80-3000 cp at 20-30 deg.c. The slow released microsphere may be also prepared into slow released implanting agent for use alone or together with chemotherapeutic and/or radiotherapeutic medicine..

The present invention relates to an anticarcinogen slow-released injection containing platinum compound and its synergist. It is composed of microsphere and solvent, in which the microsphere includes anticancer effective component and slow-released auxiliary material, the solvent is general one or special solvent containing suspension adjuvant. The anticancer effective component includes platinum compound selected from heptylplatin, loplatin, neidaplatin, oxaliplatin, denaplatin or enloplatin and/or platinum compound synergist selected from antitumor antibiotic, antimetabolite medicine, taxane and/or plant alkaloid; the slow-released auxiliary material is selected from polylactic acid copolymer, ethylene-vinylacetate copolymer, difatty acid and sebacic acid polymer and poly (fumaric acid-sebacic acid) copolymer. The suspension adjuvant is selected from sodium cellulose glycollate, and its viscosity is 100 cp-3000 cp (20 deg.C-30 deg.C). The slow-released microsphere also can be made into slow-released implant preparation.

The present invention pertains to the field of medical technique, in particular relates to application of (3aR, 5R, 11bR)-3, 3a, 5, 11b-tetrahydro-7-hydroxy-5-methyl-2H-furan (3, 2-b) naphtho (2, 3-d) pyrane-2, 6, 11-triketone, namely the application of the compound to preparation of antitumor antibiotic. The compound of the present invention has very strong cytotoxicity with an average median lethal concentration of 0.06Mug/mL in the 37 pieces of tumor cells in human body and can be taken as the strong active compound of antineoplastic. The compoumd has inhibitory action on a great variety of tumor cells in human body, and can be taken as clinical medicine or lead compound.